BiotechTube
Home/MetP Pharma/Udo Mattern
UM

Udo Mattern

Chief Executive Officer (CEO)

MetP Pharma

Therapeutic Areas

NeurologyEndocrinologyMetabolic Disorders

MetP Pharma Pipeline

DrugIndicationPhase
Brain-Targeted GLP-1/GIP Agonists (e.g., Semaglutide)Metabolic/Neurological DisordersPre-clinical
Nasal TestosteroneHormone Replacement / CNS EffectsPhase 2
Platform for NeuropeptidesVarious CNS DisordersResearch

Leadership Team at MetP Pharma

CM
Claudia Mattern
Chief Scientific Officer (CSO)
View full MetP Pharma profile